DEKK-TEC, INC.

Company Information

Company Name
DEKK-TEC, INC.
Address
725 TOPAZ STREET
NEW ORLEANS, LA, 70124-
Phone
n/a
URL
n/a
DUNS
139242184
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,108,638.00
9
SBIR Phase II
$5,405,723.00
6
STTR Phase I
$100,000.00
1

Award List

  1. Camptothecin Analogs for Cancer Therapy

    Amount: $837,217.00

    DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. PHENYLHYDRAZONES WITH ANTIESTROGEN ACTIVITIES

    Amount: $440,486.00

    SUBSTITUTED BENZOPHENONE PHENYLHYDRAZONES HAVE BEEN SYNTHESIZED AND HAVE DEMONSTRATED GOOD ANTIESTROGEN ACTIVITIES WITH LOW TO ABSENT INTRINSIC ESTROGENICITY (IN ANIMMATURE RAT UTERI ASSAY). 4,4(,)-DI ...

    SBIR Phase II 1991 Department of Health and Human Services
  3. ARYL HYDRAZONES WITH ANTICANCER ACTIVITIES

    Amount: $49,998.00

    SUBSTITUTED BENZOPHENONE PHENYLHYDRAZONES HAVE BEEN IDENTIFIED THAT POSSESS ANTIESTROGEN ACTIVITIES WITH ABSENT ESTROGENICITY. 4, 4'-DIHYDROXYBENZOPHENONE-2, 4-DINITROPHENYLHDRAZONE (A-007) HAS DEMONS ...

    SBIR Phase I 1992 Department of Health and Human Services
  4. Pyrromethene Boron Difluorides in PDT

    Amount: $50,000.00

    The overall objective is to develop new anticancer agents which are cytotoxic in photodynamic therapy (PDT). It has been shown by Morgan and Boyer that pyrromethene boron difluoride (P-BF2) complexes ...

    SBIR Phase I 1993 Department of Health and Human Services
  5. N/A

    Amount: $0.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  6. N/A

    Amount: $126,956.00

    N/A

    SBIR Phase II 2000 Department of Health and Human Services
  7. A-007: IMMUNE MODULATION OF HPV- CERVICAL CANCER

    Amount: $191,517.00

    DESCRIPTION: (Applicant's Description) 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has recently completed a Phase I clinical t ...

    SBIR Phase I 2001 Department of Health and Human Services
  8. A-007: Immune Modulation of HPV- Associated Neoplasia

    Amount: $2,300,487.00

    DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In ...

    SBIR Phase II 2005 Department of Health and Human Services
  9. CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE

    Amount: $185,641.00

    DESCRIPTION (provided by applicant): The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity for evaluation in vivo against a human osteosarc ...

    SBIR Phase I 2002 Department of Health and Human Services
  10. Clinical Development of 4-Hydroperoxyifosfamide

    Amount: $539,124.00

    DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological condit ...

    SBIR Phase II 2006 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government